Search
ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer
He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared...
Jun 1
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes...
Apr 17
The CEO of Arcus Biosciences talks TIGIT, adenosine, and HIF-2α at #ASCO24
Terry Rosen describes data presented at ASCO for TIGIT in upper GI cancers, adenosine in late state colorectal cancer, and non-ASCO data...
Jun 2, 2024
Dissecting the TIGIT battleground at #ASCO23
Arcus Biosciences CEO Terry Rosen describes the ARC-7 TIGIT data update that was presented at #ASCO23.
Jun 3, 2023
.png){kind=logo}
